Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Quarterly results
PORTOLA PHARMACEUTICALS INC (PTLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/02/2020 8-K Quarterly results
06/17/2020 8-K Quarterly results
06/15/2020 8-K Submission of Matters to a Vote of Security Holders
05/11/2020 8-K Quarterly results
05/07/2020 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...
Docs: "AGREEMENT AND PLAN OF MERGER by and among PORTOLA PHARMACEUTICALS, INC., ALEXION PHARMACEUTICALS, INC. and Odyssey Merger Sub Inc.",
"AMENDED AND RESTATED BYLAWS OF Portola Pharmaceuticals, inC."
05/05/2020 8-K Quarterly results
04/09/2020 8-K Other Events
02/26/2020 8-K Quarterly results
01/09/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million"
11/21/2019 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
11/05/2019 8-K Quarterly results
Docs: "Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update – Andexxa®/Ondexxya® Net Product Revenues of $35.7 million, a 32% Increase Over the Prior Quarter – – Andexxa Now Stocked in Approximately 550 U.S. Hospitals; 76% of U.S. Sales from Reorders – – Expanded Market Opportunity with Strong Initial Ondexxya Demand in Europe – – Strengthened Balance Sheet; Added Net Proceeds of $245 million in Third Quarter–"
08/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 7, 2019 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr...",
"Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
06/14/2019 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 13, 2019 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre..."
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2019 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update"
04/25/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 24, 2019 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr..."
03/20/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
03/01/2019 8-K Quarterly results
01/08/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Slides accompanying the January 8, 2019 Portola Pharmaceuticals, Inc. Corporate Presentation",
"Slides accompanying the January 8, 2019 Portola Pharmaceuticals, Inc. Corporate Presentation"
12/31/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 30, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"U.S. Food and Drug Administration Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa ® Generation 2 Manufacturing Process"
12/11/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 11, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"CHMP Extends Review Period for Portola Pharmaceuticals' Ondexxya ™"
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update"
10/12/2018 8-K Quarterly results
09/20/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Offer Letter between Portola Pharmaceuticals, Inc. and Scott Garland",
"Offer Letter between Portola Pharmaceuticals, Inc. and Scott Garland"
09/07/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : September 1, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐..."
08/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 9, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr...",
"Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update"
06/11/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment to the Portola Pharmaceuticals, Inc. Amended and Restated Certificate of Incorporation, as amended",
"Certificate of Amendment to the Portola Pharmaceuticals, Inc. Amended and Restated Certificate of Incorporation, as amended"
06/04/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter agreement with Bill Lis",
"Letter agreement with Bill Lis",
"Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018"
05/09/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update"
02/28/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update"
02/06/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 31, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ..."
11/06/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 6, 2017 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 6, 2017—Portola Pharmaceuticals Inc. ® will today report financial results and provide a corporate update for the quarter ended September 30, 2017. “Following FDA approval of our first product, Bevyxxa, our team has been working diligently to bring this important new medicine to patients in need, and we are pleased to report good progress with the FDA on achieving product release,” said Bill Lis, chief executive officer of Portola. “We are also continuing to advance AndexXa, the first-ever Factor Xa inhibitor antidote. This treatment is highly anticipated by the medical community and we are continuing discussions with U.S. and European regulatory authorit..."
09/13/2017 8-K Quarterly results
09/11/2017 8-K Quarterly results
08/09/2017 8-K Quarterly results
Docs: "Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy